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Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks? 
Alexander J Ansara, Dane L Shiltz, Jennifer B Slavens 
Abstract 
OBJECTIVE: To evaluate the safety and efficacy of cilostazol for secondary prevention of non-
cardioembolic ischemic stroke.  
DATA SOURCES: PubMed and MEDLINE searches were performed (January 1970-September 2011) 
using the key words cilostazol, antiplatelet, aspirin, acetylsalicylic acid, secondary stroke prevention, 
ischemic stroke, intracerebral hemorrhage, intracranial, cerebrovascular accident, and transient ischemic 
attack. Additionally, reference citations from publications identified were reviewed.  
STUDY SELECTION AND DATA EXTRACTION: Articles published in English and relevant 
primary literature evaluating the efficacy and safety of cilostazol in the secondary prevention of 
atherosclerotic ischemic stroke were included.  
DATA SYNTHESIS: Antiplatelet therapy plays a vital role in the multifaceted approach to secondary 
stroke prevention. Current American Heart Association/American Stroke Association clinical guidelines 
for secondary stroke prevention support the use of aspirin, clopidogrel, and combination aspirin/extended-
release dipyridamole. The antiplatelet, antithrombotic, and vasodilatory effects of cilostazol make it a 
potential alternative agent for atherosclerotic stroke prevention. Recent literature has demonstrated 
superior efficacy of cilostazol 100 mg twice daily for secondary stroke prevention compared to placebo 
and aspirin. Three clinical trials were reviewed (1 placebo-controlled, 2 aspirin-controlled), all of which 
were conducted in Japan or China. Cilostazol reduced the primary outcome of recurrence of stroke, with 
significantly fewer major bleeding events when compared to aspirin.  
CONCLUSIONS: Available literature suggests that cilostazol may be safer and more effective than 
aspirin in the secondary prevention of stroke in Asian patients. Further large-scale studies in more 
heterogeneous study populations are warranted to determine whether cilostazol is a viable therapeutic 
option for patients with a history of non-cardioembolic ischemic stroke.  
Stroke is the third leading cause of death in the US, accounting for 1 of every 18 deaths in 2007.
1
 
While stroke death rates have fallen from 33.5% in 1996 to 16.7% in 2007, stroke remains a 
leading cause of disability, impaired functionality, and reduced quality of life.
1
 
Atherosclerotic disease accounts for roughly 85% of the nearly 800,000 strokes that occur 
annually in the US.
1
 Optimization of secondary stroke prevention requires a multifaceted 
approach that includes blood pressure control, cholesterol-lowering medications, smoking 
cessation, diet, and exercise, among others. Another mainstay of stroke prevention is antiplatelet 
therapy. Several antiplatelet agents, including aspirin, clopidogrel, ticlopidine, and 
aspirin/extended-release dipyridamole, are currently recommended by the American Heart 
Association (AHA) and American Stroke Association as suitable options for secondary stroke 
prevention.
2
 
Aspirin is often prescribed as a first-line agent for secondary stroke prevention due to its lack of 
therapeutic monitoring, established efficacy in the treatment of acute ischemic stroke, and 
significantly lower cost compared to all other antiplatelet agents. While the cost of aspirin is 
significantly the lowest among these antiplatelet agents, its use is associated with dosage-related 
gastrointestinal (GI) and intracranial hemorrhages (ICH).
3
 Ticlopidine and clopidogrel use is 
associated with neutropenia, diarrhea, and skin rash, while up to 40% of patients taking 
aspirin/extended-release dipyridamole experience severe headaches.
4⇓–6 
Recent clinical trial evidence suggests that cilostazol, a platelet inhibitor indicated for 
intermittent claudication, may be a safer and more effective alternative than aspirin for secondary 
stroke prevention in Asian patients. AHA guidelines do not yet provide recommendations on the 
role of cilostazol for secondary stroke prevention. This article details cilostazol's mechanism of 
action as an antiplatelet agent, provides a critique of secondary ischemic stroke prevention trials 
(all conducted in either Japan or China), and compares bleeding rates with cilostazol to those of 
other secondary stroke prevention treatment options.  
Data Sources 
A literature search was performed (January 1970-September 2011) using PubMed and 
MEDLINE to identify relevant English-language review articles and clinical trials using the key 
words cilostazol, antiplatelet, aspirin, acetylsalicylic acid, secondary stroke prevention, ischemic 
stroke, intracerebral hemorrhage, intracranial, cerebrovascular accident, and transient ischemic 
attack. Reference citations of identified articles were used to identify additional literature for 
reference. Data from package inserts and unpublished clinical trials in progress (from 
www.clinicaltrials.gov) were also reviewed. Article selection was focused on the pharmacology 
of antiplatelet agents, the pathophysiology of atherosclerotic stroke, clinical trials, and safety 
analyses.  
Mechanism of Action 
Atherosclerotic vascular plaques contain smooth muscle cells, macrophages, and collagen within 
a lipid core. Plaque erosion, fissure, and/or rupture due to shear stress expose the subendothelial 
matrix, collagen, and tissue factor found within the lipid core. Each of these serves as potent 
substrates for platelet-rich thrombus formation.
7
 
Following rupture of unstable plaques, tissue factor and collagen-bound von Willebrand factor 
promote platelet adhesion and activation on the exposed subendothelial matrix surface. Activated 
platelets release adenosine diphosphate (ADP) and cyclooxygenase (COX)-produced 
thromboxane A2, mediators that promote vasoconstriction and additional platelet activation. 
Through the P2Y12 receptor, ADP stimulates platelets to express glycoprotein IIb/IIIa receptors. 
Glycoprotein IIb/IIIa receptors cross-link platelets via fibrinogen that is further cleaved into 
fibrin by activated thrombin (factor IIa) to form a stable thrombus. This thrombus occludes blood 
flow through vessels, depriving tissues of necessary oxygen, and potentially contributing to cell 
and tissue death.
7
 
Cilostazol's utility as a medication for ischemic stroke prevention extends from its Food and 
Drug Administration (FDA)–approved indication for the treatment of intermittent claudication in 
peripheral arterial disease because it exerts antiplatelet, antithrombotic, and vasodilatory effects.
5
 
As a dose-dependent antiplatelet agent with a 3- to 6-hour onset, cilostazol blocks platelet 
adenosine uptake and adenosine-induced platelet activation to prevent platelet aggregation. 
Additional antiplatelet and antithrombotic actions involve platelet- and endothelial-derived 
phosphodiesterase type 3 (PDE-3) enzyme inhibition.
8,9
 Intraplatelet cyclic adenosine 
monophosphate (cAMP) elevations due to PDE-3 inhibition prevent platelet aggregation and 
thrombus formation stimulated by thrombin, arachidonic acid, ADP, epinephrine, collagen, and 
sheer physical stress (Figure 1).
7,9–11
 In vitro and in vivo data further demonstrate that cilostazol 
induces the expression of the endothelium-derived antiplatelet compound prostacyclin, while the 
COX inhibitor aspirin prevents prostacyclin formation, allowing for platelet aggregation.
7,9
 
 
Figure 1 Cilostazol mechanisms of action. Atherosclerotic plaque rupture permits binding of TF and vWF to exposed collagen 
and subendothelial matrix to initiate the platelet activation process. Following platelet activation, platelet adenosine 
concentrations increase through reuptake while cAMP concentrations decrease through the PDE-3 enzyme metabolism. In 
combination with thrombin, epinephrine, ADP and other mediators, these actions serve to promote platelet aggregation and 
thrombus formation.7 Cilostazol inhibits PDE-3 to maintain cAMP levels while preventing platelet adenosine uptake. These 
principal actions prevent platelet aggregation, augment production of the antiplatelet prostacyclin, decrease response to platelet 
stimuli such as thrombin, epinephrine, and ADP, and also vasodilate major blood vessels that perfuse organs including the brain, 
heart, and extremities.9⇓–11 ADP = adenosine diphosphate; cAMP = cyclic adenosine monophosphate; PDE-3 = 
phosphodiesterase type 3; PGI2 = prostacyclin; TF = tissue factor; vWF = von Willebrand factor. 
Compared to cilostazol, aspirin/extended-release dipyridamole also prevents platelet adenosine 
uptake, but also inhibits cyclic guanosine monophosphate to prevent platelet activation. The 
aspirin component inhibits the COX enzyme to prevent thromboxane A2 production, platelet 
aggregation, and vasoconstriction.
6
 Clopidogrel is another FDA-approved antiplatelet agent used 
for secondary stroke prevention. Clopidogrel is activated via the CYP2C19 enzyme to selectively 
and irreversibly inhibit the binding of ADP to its platelet P2Y12 receptor and the subsequent 
ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet 
aggregation.
5
 
Cilostazol reduces vascular tone, promoting more vasodilation in vertebral and femoral arteries 
than renal arteries.
10
 Cilostazol also increases human carotid, cerebral, coronary, and dermal 
blood flow.
9,10
 Additional effects on vasculature include inhibition of human smooth muscle 
proliferation due to growth factors including insulin, insulin-like growth factor, serum growth 
factor, and platelet-derived growth factor. Emerging evidence suggests that, by inhibiting the 
PDE-3 enzyme found within human smooth muscle cells, cilostazol inhibits smooth muscle cell 
proliferation and thus may prevent and possibly even reverse intracranial atherosclerotic lesions, 
improving cerebral blood flow.
12,13
 Additionally, cilostazol increases vascular endothelial growth 
factor, which serves to repair damaged vascular epithelium.
9,10
 These combined antiplatelet, 
antithrombotic, and vascular properties all favorably contribute to cilostazol's utility for stroke 
prevention.  
Clinical Trials 
Three clinical trials encompass the body of evidence supporting the use of cilostazol as an 
alternative agent for secondary stroke prevention in Asian patients. These clinical trials include 
the placebo-controlled CSPS (Cilostazol Stroke Prevention Study) and 2 aspirin-controlled trials: 
the CASISP (Cilostazol as an Alternative to Aspirin After Ischaemic Stroke) trial and the CSPS-
2 (Cilostazol for Prevention of Secondary Stroke) trial. Comparisons and findings of these trials 
are summarized in Table 1.
11,14,15 
The impetus for conducting these trials was a relative lack of representation of Asian patients in 
stroke prevention studies, as most large-scale trials had been conducted in North American and 
Western European countries. Compared to other ethnic categories, the prevalence of 2 or more 
risk factors (diabetes, smoking, high blood pressure or cholesterol, obesity, physical inactivity) 
for stroke is lowest among Asian Americans (25.9%)
16
; therefore, the age-adjusted prevalence of 
stroke among Asian Americans 18 years of age and over remains relatively low, at 1.3%.
17
 
However, the age-adjusted incidence of ICH for individuals 55 years and older in the Chinese 
population is higher than that seen in individuals in Western populations.
18,19
 While the primary 
goal of antiplatelet therapy is to prevent ischemic events, minimizing the risk of ICH remains an 
essential focus of stroke prevention therapy. 
 
 
 
 
 
 
 CILOSTAZOL STROKE PREVENTION STUDY 
The CSPS was an intention-to-treat study conducted in Japan at 183 clinical institutions from 
April 1992 to March 1996. Patients (N = 1052; 65% male) less than 80 years old with a prior 
cerebral infarction were randomized in a double-blinded manner to receive cilostazol 100 mg 
orally twice daily (n = 526) or placebo (n = 526) starting 1-6 months after infarction.
14
 Patients 
with ICH, cardiogenic emboli, hemostatic disorders, need for non-study antiplatelet agents, 
severe cerebral deficit, dementia, or a wide variety of cardiac valve or chamber-associated 
complications were excluded, as were any pregnant or nursing women. The primary endpoint 
was the recurrence of cerebral infarction. Secondary endpoints included all-cause mortality, ICH, 
transient ischemic attack (TIA), and multiple composite endpoints including the composite of 
cerebral infarction, ICH, or TIA. Safety and adverse effects were also assessed on 4 occasions, 
including 2 interim analyses that also included assessments of efficacy.  
Mean time from the primary cerebrovascular accident until treatment initiation was 83 days in 
both treatment arms and mean duration of follow-up was 1.7 years. While the 83-day mean time 
to treatment initiation with cilostazol appears inappropriate for a secondary stroke prevention 
study, many patients were already receiving secondary stroke prevention with various other 
Table 1. Secondary Stroke Prevention Trials Utilizing Cilostazol 
Study Patient
s 
    (N) 
Patient Characteristics Treatmen
t Arms 
Treat
ment 
Durat
ion 
Primary 
Endpoint 
Results p Value 
CSPS 
(2000)14 
1052 65% male; median age 65 y; 
65% MCA stroke; 75% 
small infarction (≤1.5 cm); 
61% HTN; 51% <60 days 
since CVA 
Cilostazol 
100 mg 
bid vs 
placebo 
1.7 
Years 
Cerebral 
infarction 
Event rate 
per year: 
cilostazol 
3.37% vs 
placebo 
5.78% (RRR 
= 41.7%) 
0.015 (95% CI 
9.2% to 62.5%) 
CASISP 
(2008)15 
719 69% male; median age 60 y; 
82% modified Rankin scale 
score ≤2; 79% HTN; 62% on 
aspirin at baseline; 18% 
daily history of DM 
Cilostazol 
100 mg 
bid 
vs aspirin 
100 mg 
1 year Any stroke: 
Ischemic 
stroke, 
cerebral 
hemorrhage, 
subarachnoid 
hemorrhage 
Composite 
endpoint: 
cilostazol 
3.62% vs 
aspirin 
6.41% (540-
day 
estimated 
recurrence 
rates) 
0.62 (95% CI 0.3 to 
1.26) 
CSPS-2 
(2010)11 
2672 72% male; mean age 63 y; 
92% Rankin scale score ≤ 2; 
82% <2 months post-stroke; 
73% HTN; 42% 
hyperlipidemia; 58% on 
aspirin at baseline; 25% on 
cilostazol at baseline 
Cilostazol 
100 mg 
bid 
vs aspirin 
81 mg 
daily 
2.4 
years 
Any stroke: 
cerebral 
infarction, 
cerebral 
hemorrhage, 
subarachnoid 
hemorrhage 
Composite 
endpoint: 
cilostazol 
2.76%/y 
vs aspirin 
3.71%/y 
Ischemic 
stroke: 
cilostazol 
2.43%/y vs 
aspirin 
2.75%/y 
Composite 
endpoint: 
p = 0.0357 
(95% CI 0.564 to 
0.981) Ischemic 
stroke: p = 0.419 
(95% CI 0.65 to 
1.2) 
CASISP = Cilostazol as an Alternative to Aspirin After Ischaemic Stroke; CSPS = Cliostazol Stroke Prevention Study; CSPS-2 = 
Cilostazol for Prevention of Secondary Stroke; CVA = cerebrovascular accident; DM = diabetes mellitus; HTN = hypertension; MCA = 
middle cerebral artery; RRR = relative risk reduction. 
anticoagulant and antiplatelet agents. However, the authors do not identify the medications, 
doses, or percentages of patients utilizing these medications prior to study initiation. Baseline 
characteristics of age (65 years), blood pressure, infarction size, and past medical histories were 
comparable in both groups. Additionally, the involved arteries of the primary cerebrovascular 
infarction were comparable in both groups: middle cerebral arteries (64.7% and 66.3%) and 
vertebrobasilar arteries (19.5% and 21.3%) accounted for the majority of the infarctions in the 
cilostazol and placebo groups, respectively. It is noteworthy that approximately 75% of all 
primary cerebral infarctions were lacunar infarcts,
14
 a form of small artery occlusive stroke 
associated with the lowest rates of early recurrence and best rates of survival and motor deficit 
improvements among the various types of strokes.
20
 
Treatment with cilostazol was associated with reductions in the recurrence of cerebral infarction, 
as 30 and 57 strokes occurred in the cilostazol and placebo groups, respectively (event rates 
3.37%/year vs 5.78%/year; p = 0.015).
14
 This correlated to a relative risk reduction (RRR) of 
41.7% and a number needed to treat (NNT) of 42 patients. The greatest risk reduction (43.4% 
with cilostazol vs placebo; p = 0.0373) occurred in patients with initial lacunar infarcts, a finding 
that suggests that cilostazol may have a specific effect against small-vessel cerebrovascular 
disease.
21
 Treatment with cilostazol was also associated with favorable effects on the composite 
endpoint of cerebral infarction, ICH, or TIA (event rates 4.17%/year vs 7.06%/year; RRR 40.9%; 
p = 0.009) as well as rates of all-cause mortality during the trial period (RRR 43.8%; p = 
0.042).
14
 
ICH developed in 4 patients receiving cilostazol and 7 patients receiving placebo. While no 
ischemic or hemorrhagic strokes were fatal in the cilostazol group, there were 3 ischemic and 1 
hemorrhagic fatal strokes among the 534 patients in the placebo group. Patients receiving 
cilostazol reported significantly higher rates of mild headaches (12.8% vs 3.2%), palpitations 
(5.3% vs 0.4%), and elevated heart rates (19.0% vs 7.9%), most of which were often self-limited. 
A higher percentage of patients in the cilostazol group experienced reductions in serum 
triglycerides (6.6% cilostazol vs 2.9% placebo; p = 0.0097) and elevations in high-density 
lipoprotein levels (14.3% cilostazol vs 5.2% placebo; p = 0.00), although specific data on the use 
of lipid-lowering agents in study participants were not provided. The investigators also did not 
define, nor quantify, what entailed a reduction in triglyceride levels or an increase in high-
density lipoprotein levels.
14
 The reductions in stroke associated with cilostazol are more likely 
attributed to the antiplatelet and vasodilatory effects that result from cAMP-phosphodiesterase 
inhibition and not the antilipidemic effects observed in this trial.
22,23
 These vasodilatory effects 
also explain the significantly higher rates of headaches reported in subjects receiving cilostazol.
14
 
The ethicality of this placebo-controlled stroke trial can be questioned given that the 
AHA/American Stroke Association secondary stroke guidelines suggest antiplatelet drugs with a 
level I class A evidence recommendation in this study population.
2
 The findings demonstrate that 
cilostazol reduces the recurrence of cerebrovascular infarctions compared to placebo.
14
 The 
beneficial effects of cilostazol were apparent early, continued throughout the study, and were 
comparable in men and women, without increased rates of cerebral hemorrhage. Based on the 
CSPS data, the pilot CASISP study and larger CSPS-2 study were designed to assess the efficacy 
and safety of cilostazol as a direct comparator to aspirin in the setting of secondary stroke 
prevention.  
CILOSTAZOL AS AN ALTERNATIVE TO ASPIRIN AFTER ISCHEMIC STROKE 
Following the published results of the CSPS, data were still lacking on cilostazol versus an active 
comparator. In 2008, Huang and colleagues published CASISP, an intent-to-treat trial designed 
to assess the safety and efficacy of cilostazol versus aspirin for secondary stroke prevention.
15
 
CASISP was a randomized, double-blind, multicenter, pilot trial that enrolled 719 Chinese 
patients (69% male) who had experienced an image-diagnosed ischemic stroke. Patients were 
randomized to receive cilostazol 100 mg orally twice daily (n = 360) or aspirin 100 mg orally 
once daily (n = 359) starting 1-6 months after infarction. Patients were followed for 12-18 
months and evaluated on the primary outcome of recurrence of stroke as defined by any of the 
following: ischemic stroke, cerebral hemorrhage, or subarachnoid hemorrhage. Patients with a 
history of subarachnoid hemorrhage, ICH, cardioembolic cerebral infarct, contraindication to 
antiplatelet therapy, use of antiplatelet therapy other than cilostazol during the study period, 
severe disability, uncontrolled severe comorbidities, or modified Rankin scale score of 4 or 
greater were not eligible for inclusion in this study. A score of 4 or greater on the modified 
Rankin scale (which assigns a number between 0 and 6 to assess a patient's level of 
independence after stroke) represents moderate-to-severe disability, including patients unable to 
walk without assistance or bedridden patients requiring constant nursing care. A score of 6 is 
assigned for death.
24,25
 Specific uncontrolled severe comorbidities and disabilities qualifying 
patients for exclusion were not stated.
15
 Patients with hypertension and dyslipidemia at baseline 
were given antihypertensives and/or statins. No statement of specific agents utilized, number of 
patients affected in each treatment group, or criteria to define hypertension or dyslipidemia were 
disclosed.  
Baseline characteristics were similar between the 2 groups. Systolic blood pressure was 
significantly higher in the aspirin group at baseline (p = 0.03). These patients were treated with 
antihypertensives, with resolution of hypertension after 1 month of therapy. No statements of the 
medications utilized, number of patients treated for hypertension, or goal blood pressure were 
made. Sixty-two percent of the patients in both groups were taking aspirin prior to enrollment. 
One percent or less of the patients in each group was on cilostazol prior to enrollment. A 
majority (82%) of the patients in both groups had a modified Rankin scale score of 2 or less.
15
 
The primary endpoint was reached by 12 patients (3.33%) in the cilostazol group and 20 patients 
(5.57%) in the aspirin group, resulting in an RRR of 38.1% (95% CI 0.3 to 1.26%; p = 0.18). 
Ischemic strokes occurred in 26 patients: 11 with cilostazol (3.1%) and 15 with aspirin (4.2%), 
but this finding also did not reach statistical significance. As a component of the primary 
endpoint, hemorrhagic strokes accounted for 8% of the cilostazol-related strokes (1/12) and 25% 
of the aspirin-related strokes (RR 7.14; p = 0.038). New microbleeds and asymptomatic 
hematomas were reported less commonly in the cilostazol group than in the aspirin group; 
however, no statement of significance was disclosed. Other adverse effects reported more 
frequently in the cilostazol group were headache, dizziness, palpitations, and tachycardia. 
Extracranial bleeding was reported more frequently in the aspirin group (4% cilostazol vs 9% 
aspirin). Fecal occult bleeding, hematuria, GI bleeding, and rhinorrhagia were common types of 
extracranial bleeding.
15
 
Results of this study support a trend toward improved efficacy of cilostazol over aspirin and 
improved safety, shown by the statistically significant reduction in bleeding events in the 
cilostazol group.
15
 The finding that hemorrhagic stroke occurred less frequently with cilostazol is 
salient considering the higher incidence of cerebral hemorrhage in patients of Asian ethnicity 
relative to other ethnic groups.
26,27
 Nevertheless, based on the hypothesis-generating results of 
the CASISP trial, further analysis in a large Phase 3 trial was warranted to evaluate the trend 
toward improved efficacy of cilostazol over aspirin for secondary stroke prevention.  
CILOSTAZOL STROKE PREVENTION STUDY 2 
The CSPS-2 trial was designed to establish noninferiority of cilostazol when compared to 
aspirin.
11
 Similar to the CSPS trial, the CSPS-2 trial was conducted exclusively in Japan at 278 
sites between December 2003 and December 2008. Patients (N = 2672; 72% male) between the 
ages of 20 and 79 years with a prior cerebral infarction within the past 6.5 months, with no 
evidence of cardiogenic emboli, were randomized in double-blinded fashion to receive cilostazol 
100 mg orally twice daily (n = 1337) or aspirin 81 mg orally once daily (n = 1335) for 1-5 years. 
Patients were excluded if they had contraindications to cilostazol or aspirin, congestive heart 
failure, peptic ulcer disease, renal failure, liver disease, cardiac diseases associated with 
cardioemboli, or planned revascularization procedures. Prior to study entry, 83% of patients were 
receiving either cilostazol (25%) or aspirin (58%), although concurrent use of thienopyridines or 
other drugs affecting platelet function or hemostasis was prohibited. The primary endpoint was 
the first recurrence of stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid 
hemorrhage). Secondary endpoints included death from any cause, ICH, cardiovascular events, 
and hemorrhage requiring hospital admission.  
Baseline characteristics of the 2 groups were comparable overall, with the exception of 
significantly higher percentages of patients in the aspirin arm receiving lipid-lowering (30% vs 
27%; p = 0.03) and antihypertensive medications (75% vs 67%; p < 0.0001). Blood pressures, 
however, were similarly controlled in both groups throughout the study period. A large 
proportion of patients (92%) had modified Rankin scores of 0-2, while 46% of patients had a 
score of 1. Similar proportions of patients had prior subtypes of lacunar infarcts (65% in both 
groups) and atherothrombotic strokes (cilostazol 33% vs aspirin 31%).
11
 
Data from the Antithrombotic Trialists’ Collaboration meta-analysis of antiplatelet therapy in 
patients with cerebral infarction and the CSPS trial results suggested hazard ratios of 0.6 for 
aspirin and cilostazol when compared to placebo.
28
 As a result, a predefined hazard ratio of 1.33 
for the noninferiority of cilostazol was set prior to initiation of the CSPS-2 trial.
11
 The adjusted 
significance level for superiority testing was set at 0.0471.  
After a mean duration of treatment of 2.4 years, treatment with cilostazol was associated with 
significant reductions in the primary endpoint of stroke, as there were 82 strokes in the cilostazol 
group and 119 strokes in the aspirin group (event rates 2.76%/year vs 3.71%/year, respectively; 
RRR 25.7%; p = 0.0357). The p value was lower than the adjusted level of significance for 
testing of superiority (p = 0.0471); therefore, a conclusion that cilostazol may be superior to 
aspirin 81 mg daily for the secondary prevention of any stroke is plausible. The secondary 
endpoint of cerebral infarction, however, demonstrated similar efficacy between cilostazol and 
aspirin, as event rates were 2.43% and 2.75% per person-year, respectively (p = 0.419). 
Consequently, the comparative efficacies of cilostazol and aspirin for the secondary prevention 
of ischemic stroke are similar. No differences were observed in the incidences of death or 
cardiovascular events.
11
 
As observed in the CASISP study, the risk of hemorrhagic events was notably lower in the 
cilostazol group, as hemorrhagic events occurred in 57 aspirin-treated patients and only 23 
cilostazol-treated patients (RRR 54.2%; p = 0.0004). The composite of symptomatic cerebral, 
thalamic, intraventricular, cerebellar, or putamen hemorrhages occurred less frequently with 
cilostazol than aspirin (8 vs 27; p = 0.0027), as did the rate of hospitalization secondary to GI 
bleeding (21 vs 8; p = 0.026). As seen in the CSPS trial, patients receiving cilostazol in the 
CSPS-2 trial reported significantly higher rates of mild headaches (23% vs 16%; p < 0.0001), 
palpitations (12% vs 5%; p < 0.0001), and tachycardia (7% vs 2%; p < 0.0001). Overall, a higher 
percentage of patients in the cilostazol group discontinued treatment (20% vs 12%) due to 
adverse effects.
11
 
While cilostazol resulted in a 41.7% RRR compared to placebo in CSPS and a 38.1% RRR 
compared to aspirin in the CASISP study, decisive conclusions regarding the comparative 
efficacy between cilostazol and aspirin could not be made. In the CSPS-2 trial, the treatment 
effects of aspirin and cilostazol in the 83% of patients taking these medications prior to study 
initiation cannot be ascertained. Early initiation of antiplatelet therapy for secondary prevention 
is essential, but the CSPS-2 study is confounded by the late start date of the study drugs, as only 
31% of patients in each treatment arm were initiated on their study drugs within 28 days from the 
onset of cerebral infarction.
11
 Stroke recurrence rates are estimated to be highest (8.6% of 
patients) within the first 6 months of the first incident.
29
 More recent data suggest recurrence 
rates up to 18% at 3 months after a TIA or stroke.
30
 It is therefore difficult to accurately quantify 
the impact of cilostazol on secondary stroke prevention given these study limitations.  
The results of CSPS-2, however, support the findings of the CASISP study and demonstrate that 
cilostazol significantly lowers the risks of stroke and cerebral hemorrhage when compared to low 
doses (81-100 mg daily) of aspirin.
11
 The reduction in the composite stroke endpoint is likely 
driven by significant reductions in hemorrhagic stroke and the comparative efficacies of aspirin 
and cilostazol specific to ischemic stroke are similar.  
CILOSTAZOL BLEEDING EVENTS 
Trials that evaluate bleeding risk with antithrombotic therapies vary in their definition and 
classification of hemorrhagic events. These descriptions depend on the assessment method used 
when either a universal definition was not available or not utilized at the time of data collection. 
In addition, the description of a bleeding event and its severity are sometimes inadequately 
defined, leaving the bleeding risk and severity of a given antithrombotic agent somewhat open to 
reader interpretation. Consequently, it proves difficult to accurately stratify and compare 
severities of bleeding events between studies that evaluate safety. A literature-based effort to 
classify the terminology for hemorrhagic events is provided below.  
Any bleeding includes major and minor hemorrhagic events, but intracranial bleeding cases may 
be omitted depending on the trial.
14,31,32
 The definition of major bleeding can vary, but it 
typically includes bleeding with persistent sequelae that contributes to significant disability, 
intraocular bleeding leading to significant vision loss, transfusion of 3 or more units of packed 
red blood cells, or need for hospitalization. A major hemorrhagic event may be life-threatening 
or non–life-threatening.11,31,33,34 Minor bleeding does not meet major bleeding criteria and may 
include epistaxis or other bleeding that does not require transfusion, cause disability, or require 
hospitalization.
31,34
 Life-threatening bleeding generally refers to a fatal bleeding event, a 
decrease in hemoglobin of 5 g/dL or more, significant hypotension requiring inotropic support, 
symptomatic intracranial hemorrhage, need for emergent surgical intervention, or need for 
transfusion of 4 units or more of packed red blood cells.
33,34
 
Despite these inherent limitations that complicate comparisons, the bleeding incidences reported 
in various stroke trials that included placebo, cilostazol, aspirin, dipyridamole, and/or clopidogrel 
are reported with p values and confidence intervals, when available, in Table 2.
31–37
 
Table 2. Major, Minor, and Fatal or Life-Threatening Bleeding in Secondary Stroke Prevention Trials 
Drug Studies 
Major Bleeding 
Incidence (%) 
Minor Bleeding 
Incidence (%) 
Fatal or Life-
Threatening Bleeding 
Incidence (%)  
Cilostazol Shinohara (2010),11 
Gotoh (2000),14 Huang 
(2008)15 
0.28a Not defined None reported 
Dipyridamole Diener (1996)31 0.4 Not defined 0.4 
Clopidogrel Diener (2004),33 Sacco 
(2008),34 CAPRIE 
steering committee 
(1996)32 
1-3.6 1 1 
Aspirin (30-325 
mg/day) 
CAPRIE steering 
committee (1996),32 
ESPRIT study group 
(2006),35 CAST 
collaborative group 
(1997),36 IST 
collaborative group 
(1997)37 
1.95-3.9 12.2 0.8-1.2 
Aspirin + clopidogrel Diener (2004)33 2 3 3 
Aspirin + dipyridamole Diener (1996),31Sacco 
(2008),34 ESPRIT 
study group (2006)35 
2.6-4.1 12.5 1.6 
aA cilostazol meta-analysis demonstrated that the serious bleeding incidence in peripheral arterial disease populations ranges 
from 0.4% to 2.8%.38 
Data from these trials demonstrate lower rates of major bleeding, including intracerebral 
hemorrhages, associated with cilostazol use when compared to other AHA-approved antiplatelet 
agents for secondary stroke prevention. A meta-analysis of cilostazol trials demonstrated that the 
serious bleeding incidence in peripheral arterial disease populations ranges from 0.4% to 2.8%.
38 
Discussion 
Collective data from the CSPS, CASISP, and CSPS-2 trials suggest that cilostazol may be more 
effective than aspirin in the secondary prevention of stroke and is associated with lower rates of 
hemorrhagic stroke in the Asian population.
11,14,15
 While the primary endpoint in CASISP did not 
reach statistical significance, this may be a direct result of small sample size and short follow-up 
period. On the basis of this collective evidence, Japanese guidelines for the management of 
stroke recommend cilostazol as a treatment alternative for secondary prevention of cerebral 
infarction.
39
 
The use of aspirin as a first-line agent for the secondary prevention of ischemic stroke is 
supported by the AHA and American Stroke Association.
2
 The low NNT of 42 patients for 
secondary stroke prevention with cilostazol in the CSPS trial is comparable to the NNT of 35 
patients when low-dose aspirin (50 mg daily) was compared to placebo for secondary stroke 
prevention in the European Stroke Prevention Study 2 (ESPS-2), a study in which aspirin alone 
resulted in a 21% RRR compared to placebo.
31
 While cilostazol resulted in a 42% RRR 
compared to placebo in CSPS,
14
 direct comparisons between the efficacy of cilostazol and 
aspirin in the CSPS and ESPS-2 trials are not statistically valid due to differences in patient 
demographics, as CSPS was conducted exclusively in Asian patients while ESPS-2 participants 
were primarily white. Additionally, the large differences in the percentages of patients with 
ischemic heart disease and diabetes in these 2 trials make it difficult to directly compare the 
efficacy of cilostazol and aspirin across trials.  
Calculations from the Antiplatelet and Antithrombotic Trialists’ Collaboration data demonstrate 
that aspirin and thienopyridines are associated with an NNT of 26-28 patients to prevent one 
stroke in a 2.5- to 3-year treatment period.
28,40
 The NNT for cilostazol from a subgroup analysis 
of hypertensive or diabetic patients in the CSPS study was 18.7 patients per 3-year treatment 
period.
41
 
Despite these promising data, uncertainty regarding cilostazol's utility as a first-line agent for 
secondary stroke prevention remains. The AHA/American Stroke Association have identified 
racial disparities in stroke care of Asian American patients and recommend more research in this 
population.
42
 Further prospective, randomized trials are warranted in a more diverse patient 
population to determine if the benefits of cilostazol on stroke reduction are universal or specific 
to the Chinese and Japanese patient populations. Treatment with cilostazol is significantly more 
expensive than treatment with over-the-counter aspirin. Additionally, while the risk of major 
bleeding is lower with cilostazol in the Asian study population, a high rate of discontinuation 
(20%) due to adverse effects was associated with cilostazol use in the CSPS-2 trial. Although 
cilostazol has been proven to reduce incidence of hemorrhagic strokes, it has not yet been proven 
to be more effective than aspirin in the secondary prevention of strokes that are ischemic in 
nature.  
While cilostazol's antiplatelet effects occur within 3-6 hours of initiation,
8
 prospective clinical 
data supporting its use in the treatment of acute (<48 hours) ischemic stroke are limited to one 
small study that demonstrated noninferiority and similar rates of bleeding with cilostazol 200 mg 
daily when compared to aspirin 300 mg.
43
 Treatment with cilostazol should therefore be reserved 
as an option for secondary prevention in Asian patients who have already received treatment 
with an appropriate alternative antiplatelet agent. Based on available data, the optimal time to 
initiate treatment with cilostazol after ischemic stroke remains undefined and warrants further 
investigation.  
Summary 
Cilostazol use for the secondary prevention of stroke may be optimal for Asian patients at high 
risk of hemorrhagic events or intolerant to aspirin. However, further large-scale trials with more 
heterogeneous study populations are warranted before treatment with cilostazol can be 
universally recommended as a first-line pharmacologic agent for secondary stroke prevention.  
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